Trypsin-EDTA Solution for Cell Dissociation Market Report 2026

The trypsin-edta solution for cell dissociation market size has grown strongly in recent years. It will grow from $1.33 billion in 2025 to $1.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to expansion of cell culture based research activities, increasing production of biologics and vaccines, wider adoption of adherent cell lines, growth of academic and clinical research laboratories, improved availability of standardized reagents.

The trypsin-edta solution for cell dissociation market size is expected to see strong growth in the next few years. It will grow to $2.03 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing demand for cell-based therapies, increasing scale-up of biopharmaceutical manufacturing, rising focus on automation in cell processing, expansion of regenerative medicine research, higher regulatory emphasis on process consistency. Major trends in the forecast period include increasing adoption of serum-free cell dissociation reagents, rising demand for consistent cell harvesting solutions, growing use in large-scale biomanufacturing, expansion of stem cell and primary cell applications, enhanced focus on reproducibility and cell viability.

The rising prevalence of chronic diseases is expected to drive growth in the trypsin-EDTA solution for cell dissociation market in the coming years. Chronic diseases are long-term health conditions, such as diabetes, heart disease, and chronic respiratory disorders, that often require ongoing management. Their increasing incidence is fueled by factors such as aging populations, lifestyle-related risk factors like poor diet and physical inactivity, and advances in medical technology that improve detection and management. Trypsin-EDTA solutions are widely used in chronic disease research to efficiently detach and harvest cells from tissues or cultures for further analysis or therapeutic applications. For example, in February 2024, the World Health Organization (WHO) reported approximately 20 million new cancer cases in 2022, along with 9.7 million deaths. By 2050, new cancer cases are projected to exceed 35 million, representing a 77% increase from 2022. This rising prevalence of chronic diseases is fueling demand for trypsin-EDTA solutions in research and cell-based applications.

The growing demand for personalized medicine is also contributing to the expansion of the trypsin-EDTA solution for cell dissociation market. Personalized medicine tailors treatments and healthcare decisions to an individual’s genetic profile, needs, and characteristics. Its growth is driven by advancements in genomics, targeted therapies, and the increasing need for precise interventions for chronic diseases. Trypsin-EDTA solutions facilitate personalized medicine by enabling efficient cell culture and manipulation, which are essential for the development of cell-based therapies and regenerative medicine. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The 2023 approvals also included seven cancer drugs and three for other conditions. This rising demand for personalized treatments is boosting the adoption of trypsin-EDTA solutions in research and therapeutic applications.

Leading companies in the trypsin-EDTA solution for cell dissociation market are focusing on innovative products, such as animal-based extracellular matrix (ECM) dissociation solutions, to gain a competitive edge. These solutions, derived from animal sources, help break down ECM components to efficiently detach cells from tissues or culture surfaces. For example, in February 2023, TheWell Bioscience, a US-based biomedical technology company, launched the VitroGel Organoid Recovery Solution. This solution enables rapid and efficient recovery of organoids from both animal-based ECM and synthetic VitroGel hydrogels. It achieves complete dissociation of animal-based ECM in just 2 minutes, with the full cell harvesting process completed in 15 minutes, compared to over 60 minutes with leading alternatives. Designed for high-quality organoid recovery, it ensures superior yields, cell viability, and integrity for passaging, cryopreservation, or biochemical analysis. Additionally, it operates at room temperature, eliminating the need for heating or cooling equipment and supporting full laboratory automation for high-throughput organoid production.

Major companies operating in the trypsin-edta solution for cell dissociation market are Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group AG, VWR International LLC, Sartorius AG, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, MP Biomedicals LLC, American Type Culture Collection (ATCC), Cyagen Biosciences Inc., HiMedia Laboratories Private Limited, FUJIFILM Irvine Scientific Inc., Nacalai Tesque Inc., Creative Dynamics Inc., PromoCell GmbH, Biological Industries Israel Beit Haemek Ltd., Worthington Biochemical Corporation, Capricorn Scientific GmbH, PAN-Biotech GmbH, Cell Applications Inc., Innovative Cell Technologies Inc., Wisent Bioproducts Inc., ZenBio Inc.

North America was the largest region in the trypsin-EDTA solution for cell dissociation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trypsin-edta solution for cell dissociation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the trypsin-edta solution for cell dissociation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the trypsin-edta solution for cell dissociation market by increasing costs of imported enzymes, chelating agents, sterile packaging materials, and laboratory-grade chemicals used in reagent manufacturing. Biopharmaceutical and vaccine production facilities in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces cost pressure on export-oriented reagent supply chains. These tariffs are increasing reagent pricing and procurement costs for research laboratories. However, they are also encouraging local reagent manufacturing, regional sourcing of biochemical inputs, and investments in domestic life science supply chains.

The trypsin-edta solution for cell dissociation market research report is one of a series of new reports that provides trypsin-edta solution for cell dissociation market statistics, including trypsin-edta solution for cell dissociation industry global market size, regional shares, competitors with a trypsin-edta solution for cell dissociation market share, detailed trypsin-edta solution for cell dissociation market segments, market trends and opportunities, and any further data you may need to thrive in the trypsin-edta solution for cell dissociation industry. This trypsin-edta solution for cell dissociation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Trypsin-EDTA solution is a cell dissociation reagent that combines trypsin, an enzyme that digests proteins, with EDTA, a chelating agent that binds calcium ions, to detach adherent cells from the surfaces of culture vessels for further processing or analysis. It is widely used because it efficiently breaks down proteins and disrupts cell adhesion, enabling the harvesting of cells from culture surfaces.

The main types of trypsin-EDTA solutions for cell dissociation are 0.25% and 0.05% solutions. The 0.25% trypsin-EDTA solution contains 0.25% trypsin combined with EDTA and is commonly used in cell culture to detach adherent cells by breaking down adhesion proteins. These solutions are distributed through various channels, including online platforms, direct sales, and retail outlets, and are applied in areas such as insulin production, vaccine manufacturing, cell culture, and other biotechnological processes.

The trypsin-EDTA solution for cell dissociation market consists of sales of buffered trypsin-EDTA solution, trypsin-free cell dissociation solutions, enzyme-free cell dissociation solutions and trypsin- EDTA solutions with phenol red. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.